An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by an inadequate response to two or more oral antidepressants (OADs).

Compared with placebo, esketamine at 56-mg and 84-mg doses was associated with a significant reduction in depressive symptoms at day 28 (P < .001 for both), with corresponding effect sizes of 0.48 ...

Made from esketamine, Spravato—one of two mirror-image molecules found in the anaesthetic ketamine—was approved earlier in 2019 for adults with major depressive disorder who did not respond to ...